UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 323

Sortiert nach

Antimicrobial resistance: Audit tool limitations

British dental journal, 2018-09, Vol.225 (6), p.463-463

Cannell, P

2018

Volltextzugriff (PDF)

Skill mix - a paradigm shift?

British dental journal, 2016-03, Vol.220 (6), p.307-308

Cannell, P

2016

Volltextzugriff (PDF)

Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation

Internal medicine journal, 2015-12, Vol.45 (12), p.1286-1292

2015

Volltextzugriff (PDF)

Evaluation of the end user (dentist) experience of undertaking clinical audit in the post April 2001 general dental services (GDS) scheme

British dental journal, 2012-09, Vol.213 (5), p.E7-E7

Cannell, P J

2012

Volltextzugriff (PDF)

Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients

Bone marrow transplantation (Basingstoke), 2014-01, Vol.49 (1), p.17-23

2014

Volltextzugriff (PDF)

A PCT-wide collaborative clinical audit selecting recall intervals for patients according to risk

British dental journal, 2011-03, Vol.210 (6), p.E8-E8

Cannell, P J

2011

Volltextzugriff (PDF)

Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study

Bone marrow transplantation (Basingstoke), 2014-05, Vol.49 (5), p.691-698

2014

Volltextzugriff (PDF)

P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐6 ARM‐A INTERIM ANALYSIS

HemaSphere, 2022-06, Vol.6 (Suppl), p.831-832

2022

Volltextzugriff (PDF)

P590: PRELIMINARY SAFETY AND EFFICACY OF BGB‐11417, A POTENT AND SELECTIVE B‐CELL LYMPHOMA 2 (BCL2) INHIBITOR, IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML)

HemaSphere, 2022-06, Vol.6, p.489-490

2022

Volltextzugriff (PDF)

Delivery of postgraduate dental education to meet the needs of general dental practice - A case study

British dental journal, 2005-03, Vol.198 (6), p.367-369

Cannell, P

2005

Volltextzugriff (PDF)

Lower Dose Lenalidomide-Dexamethasone is Less Toxic and does not Compromise Efficacy for Patients with Relapsed/Refractory multiple myeloma who are aged ≥60 years and/or with renal impairment and/or with thrombocytopenia

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e284-e285

2015

Volltextzugriff (PDF)

Hematopoietic Stem/Progenitor Cells and Engineering: ABO INCOMPATIBILITY DOES NOT SIGNIFICANTLY INFLUENCE INFUSION, TRANSFUSION OR SURVIVAL OUTCOMES AFTER PERIPHERAL BLOOD ALLOGENEIC PROGENITOR CELL TRANSPLANTATION IRRESPECTIVE OF WHETHER INCOMPATIBLE PRODUCTS ARE WASHED PRIOR TO INFUSION

Cytotherapy (Oxford, England), 2023-05, Vol.25 (6), p.S126-S127

2023

Volltextzugriff (PDF)

406 - Hematopoietic Stem/Progenitor Cells and Engineering: ABO INCOMPATIBILITY DOES NOT SIGNIFICANTLY INFLUENCE INFUSION, TRANSFUSION OR SURVIVAL OUTCOMES AFTER PERIPHERAL BLOOD ALLOGENEIC PROGENITOR CELL TRANSPLANTATION IRRESPECTIVE OF WHETHER INCOMPATIBLE PRODUCTS ARE WASHED PRIOR TO INFUSION

Cytotherapy (Oxford, England), 2023-05, Vol.25 (6), p.S126-S127

2023

Volltextzugriff (PDF)

A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2004-08, Vol.34 (3), p.241-247

2004

Volltextzugriff (PDF)

Cord blood transplantation in Western Australia

Internal medicine journal, 2012-09, Vol.42 (9), p.1008-1013

2012

Volltextzugriff (PDF)

Hematopoietic Stem/Progenitor Cells and Engineering: WASHING OF ABO INCOMPATIBLE ALLOGENEIC PERIPHERAL BLOOD STEM CELL PRODUCTS IS ASSOCIATED WITH LESS INFUSION REACTIONS BUT SIMILAR TRANSFUSION BURDEN AND TRANSPLANT OUTCOMES

Cytotherapy (Oxford, England), 2022-05, Vol.24 (5), p.S103

2022

Volltextzugriff (PDF)

Autologous stem cell transplantation in systemic sclerosis: a systematic review

Clinical and experimental rheumatology, 2017-09, Vol.35 Suppl 106 (4), p.198

2017

Volltextzugriff (PDF)

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Blood, 2012-08, Vol.120 (8), p.1570-1580

2012

Volltextzugriff (PDF)

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Haematologica (Roma), 2015-09, Vol.100 (9), p.1139

2015

Volltextzugriff (PDF)

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Haematologica (Roma), 2015-04, Vol.100 (4), p.479

2015

Volltextzugriff (PDF)

Investors in People: what is it all about?

British dental journal, 2001-08, Vol.191 (4), p.175-178

Cannell, P.

2001

Volltextzugriff (PDF)

Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma

Bone marrow transplantation (Basingstoke), 1999-12, Vol.24 (11), p.1213-1217

1999

Volltextzugriff (PDF)

Audits

British dental journal, 2005-04, Vol.198 (7), p.385-385

2005

Volltextzugriff (PDF)

Prolonged profound abciximab associated immune thrombocytopenia complicated by transient multispecific platelet antibodies

Heart (British Cardiac Society), 2004-09, Vol.90 (9), p.e55-e55

2004

Volltextzugriff (PDF)

Safety and efficacy results from an international Expanded Access Programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients

Internal medicine journal, 2009-05, Vol.39 (5), p.290-295

2009

Volltextzugriff (PDF)

1 – 25 von 323

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(281)
Mit Volltextzugriff
(283)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(323)
Japanisch
(38)

Erscheinungsjahr

n.n

Thema

Science & Technology
(208)
Life Sciences & Biomedicine
(168)
Humans
(120)
Biological And Medical Sciences
(83)
Female
(74)
Male
(54)
Fundamental And Applied Biological Sciences. Psychology
(43)
Adult
(42)
Medical Sciences
(41)
Animals
(37)
Middle Aged
(36)
Physical Sciences
(36)
Hematology
(27)
Oncology
(24)
Physics
(22)
Aged
(20)
Technology
(20)
Adolescent
(19)
Exact Sciences And Technology
(19)
Pharmacology. Drug Treatments
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Antimicrobial resistance: Audit tool limitations

Skill mix - a paradigm shift?

Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation

Evaluation of the end user (dentist) experience of undertaking clinical audit in the post April 2001 general dental services (GDS) scheme

Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients

A PCT-wide collaborative clinical audit selecting recall intervals for patients according to risk

Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study

P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐6 ARM‐A INTERIM ANALYSIS

P590: PRELIMINARY SAFETY AND EFFICACY OF BGB‐11417, A POTENT AND SELECTIVE B‐CELL LYMPHOMA 2 (BCL2) INHIBITOR, IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML)

Delivery of postgraduate dental education to meet the needs of general dental practice - A case study

Lower Dose Lenalidomide-Dexamethasone is Less Toxic and does not Compromise Efficacy for Patients with Relapsed/Refractory multiple myeloma who are aged ≥60 years and/or with renal impairment and/or with thrombocytopenia

Hematopoietic Stem/Progenitor Cells and Engineering: ABO INCOMPATIBILITY DOES NOT SIGNIFICANTLY INFLUENCE INFUSION, TRANSFUSION OR SURVIVAL OUTCOMES AFTER PERIPHERAL BLOOD ALLOGENEIC PROGENITOR CELL TRANSPLANTATION IRRESPECTIVE OF WHETHER INCOMPATIBLE PRODUCTS ARE WASHED PRIOR TO INFUSION

406 - Hematopoietic Stem/Progenitor Cells and Engineering: ABO INCOMPATIBILITY DOES NOT SIGNIFICANTLY INFLUENCE INFUSION, TRANSFUSION OR SURVIVAL OUTCOMES AFTER PERIPHERAL BLOOD ALLOGENEIC PROGENITOR CELL TRANSPLANTATION IRRESPECTIVE OF WHETHER INCOMPATIBLE PRODUCTS ARE WASHED PRIOR TO INFUSION

A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation

Cord blood transplantation in Western Australia

Hematopoietic Stem/Progenitor Cells and Engineering: WASHING OF ABO INCOMPATIBLE ALLOGENEIC PERIPHERAL BLOOD STEM CELL PRODUCTS IS ASSOCIATED WITH LESS INFUSION REACTIONS BUT SIMILAR TRANSFUSION BURDEN AND TRANSPLANT OUTCOMES

Autologous stem cell transplantation in systemic sclerosis: a systematic review

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Investors in People: what is it all about?

Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma

Audits

Prolonged profound abciximab associated immune thrombocytopenia complicated by transient multispecific platelet antibodies

Safety and efficacy results from an international Expanded Access Programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients

Suchergebnisse filtern